Symphogen Opens US Operations in Princeton, New Jersey - Gilde Healthcare

Symphogen Opens US Operations in Princeton, New Jersey

2. November 2009

-US Subsidiary Supports Expanding Opportunities for Symphogen’s Novel Antibody Pipeline and Discovery and Expression Platforms-

COPENHAGEN, Denmark and PRINCETON, NJ – Symphogen A/S today announced the opening of its United States headquarters in Princeton, New Jersey. Adriann Sax, Symphogen’s recently appointed Chief Business Officer, will head the Company’s US business which will operate as Symphogen, Inc., a wholly-owned subsidiary of Symphogen A/S.

“This is the optimal time to strengthen Symphogen’s global presence as our novel pipeline is advancing into the later-stages of clinical development,”

said Kirsten Drejer, Ph.D., CEO of Symphogen.
Ms. Sax added,

“Antibody therapeutics and technologies continue to drive significant value for the pharmaceutical industry.  New Jersey has long been recognized as good centralized location for bioscience companies with global development programs and multiple worldwide partnerships, so it was an easy decision for Symphogen to base our US business here.  With Symphogen’s growing pipeline and leading antibody discovery and expression technologies, we are excited about the company’s future prospects and hope to capitalize on these opportunities by having broad access to physicians, patients and partners.”

About Symphogen

Symphogen is developing superior antibody therapeutics to help people with serious diseases.  With its proprietary SymplexTM discovery and SympressTM manufacturing platforms, the company captures the diversity and specificity of the natural immune response in rationally designed recombinant antibody compositions.  Symphogen is maturing a diversified pipeline of internal and partnered products across multiple indications including cancer and infectious disease.  Symphogen is a private biopharmaceutical company with more than 70 employees, and its headquarters are based in Copenhagen, Denmark.  www.symphogen.com

Gilde Healthcare company CatalYm announces leadership changes to accelerate visugromab late-stage clinical development

Gilde Healthcare company CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today announced changes to its executive leadership team to support its next stage of growth. The appointments of Clinton Musil as Chief...
15. September 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of tumor...
10. September 2025

Gilde Healthcare ernennt Dr. Christian Stark zum Group CEO ihrer global operierenden Medizintechnikgruppe

Die Medizintechnikgruppe, zu der zwei Hersteller chirurgischer Instrumente aus der Region Tuttlingen gehören, Koscher & Würtz und Christian Diener, hat Dr. Christian Stark mit Wirkung zum 1. September 2025 zum Chief Executive Officer (CEO) berufen....
3. September 2025